Replies to post #157383 on Biotech Values

[iandy]

Elan

what parts? all they have is the cash and the tysabri royalty.

You are essentially correct. So is Dew:

Pharma companies per se do not generally acquire firms for their royalty streams.

I was thinking an investor might make an offer.

I doubt Royalty Pharma will not increase their offer. I believe the initial offer in similar situations is usually not the last.

Tysabri sales have been good and I would expect they might improve now that Biogen derives more income from it.

Having owned this equity for a number of years, I will be very pleased when I sell the remainder of my holdings.